- Home
- BGLC vs POLA Comparison
BGLC vs POLA Comparison
Compare BGLC & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- POLA
- Stock Information
- Founded
- BGLC 2017
- POLA 1979
- Country
- BGLC Malaysia
- POLA United States
- Employees
- BGLC N/A
- POLA N/A
- Industry
- BGLC Medical Specialities
- POLA Industrial Machinery/Components
- Sector
- BGLC Health Care
- POLA Miscellaneous
- Exchange
- BGLC Nasdaq
- POLA Nasdaq
- Market Cap
- BGLC 7.6M
- POLA N/A
- IPO Year
- BGLC N/A
- POLA 2016
- Fundamental
- Price
- BGLC $0.37
- POLA $0.47
- Analyst Decision
- BGLC
- POLA
- Analyst Count
- BGLC 0
- POLA 0
- Target Price
- BGLC N/A
- POLA N/A
- AVG Volume (30 Days)
- BGLC 117.9K
- POLA 452.7K
- Earning Date
- BGLC 11-20-2024
- POLA 11-12-2024
- Dividend Yield
- BGLC N/A
- POLA N/A
- EPS Growth
- BGLC N/A
- POLA N/A
- EPS
- BGLC N/A
- POLA N/A
- Revenue
- BGLC $9,183,168.00
- POLA $11,950,000.00
- Revenue This Year
- BGLC N/A
- POLA $6.72
- Revenue Next Year
- BGLC N/A
- POLA N/A
- P/E Ratio
- BGLC N/A
- POLA N/A
- Revenue Growth
- BGLC N/A
- POLA N/A
- 52 Week Low
- BGLC $0.31
- POLA $0.32
- 52 Week High
- BGLC $3.39
- POLA $0.99
- Technical
- Relative Strength Index (RSI)
- BGLC 32.80
- POLA 49.24
- Support Level
- BGLC $0.38
- POLA $0.44
- Resistance Level
- BGLC $0.49
- POLA $0.54
- Average True Range (ATR)
- BGLC 0.02
- POLA 0.07
- MACD
- BGLC -0.01
- POLA -0.01
- Stochastic Oscillator
- BGLC 5.94
- POLA 20.00
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.